Cargando…

Functional inhibition related to structure of a highly potent insulin-specific CD8 T cell clone using altered peptide ligands

Insulin-reactive CD8 T cells are amongst the earliest islet-infiltrating CD8 T cells in NOD mice. Cloned insulin B15–23-reactive cells (designated G9C8), restricted by H-2K(d), are highly diabetogenic. We used altered peptide ligands (APL) substituted at TCR contact sites, positions (p)6 and 8, to i...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrich de Marquesini, Liliana G, Moustakas, Antonis K, Thomas, Ian J, Wen, Li, Papadopoulos, George K, Wong, F Susan
Formato: Texto
Lenguaje:English
Publicado: WILEY-VCH Verlag 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901522/
https://www.ncbi.nlm.nih.gov/pubmed/18157812
http://dx.doi.org/10.1002/eji.200737762
_version_ 1782183692876120064
author Petrich de Marquesini, Liliana G
Moustakas, Antonis K
Thomas, Ian J
Wen, Li
Papadopoulos, George K
Wong, F Susan
author_facet Petrich de Marquesini, Liliana G
Moustakas, Antonis K
Thomas, Ian J
Wen, Li
Papadopoulos, George K
Wong, F Susan
author_sort Petrich de Marquesini, Liliana G
collection PubMed
description Insulin-reactive CD8 T cells are amongst the earliest islet-infiltrating CD8 T cells in NOD mice. Cloned insulin B15–23-reactive cells (designated G9C8), restricted by H-2K(d), are highly diabetogenic. We used altered peptide ligands (APL) substituted at TCR contact sites, positions (p)6 and 8, to investigate G9C8 T cell function and correlated this with structure. Cytotoxicity and IFN-γ production assays revealed that p6G and p8R could not be replaced by any naturally occurring amino acid without abrogating recognition and functional response by the G9C8 clone. When tested for antagonist activity with APL differing from the native peptide at either of these positions, the peptide variants, G6H and R8L showed the capacity to reduce the agonist response to the native peptide. The antagonist activity in cytotoxicity and IFN-γ production assays can be correlated with conformational changes induced by different structures of the MHC-peptide complexes, shown by molecular modeling. We conclude that p6 and p8 of the insulin B15–23 peptide are very important for TCR stimulation of this clone and no substitutions are tolerated at these positions in the peptide. This is important in considering the therapeutic use of peptides as APL that encompass both CD4 and CD8 epitopes of insulin.
format Text
id pubmed-2901522
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher WILEY-VCH Verlag
record_format MEDLINE/PubMed
spelling pubmed-29015222010-07-15 Functional inhibition related to structure of a highly potent insulin-specific CD8 T cell clone using altered peptide ligands Petrich de Marquesini, Liliana G Moustakas, Antonis K Thomas, Ian J Wen, Li Papadopoulos, George K Wong, F Susan Eur J Immunol Molecular immunology Insulin-reactive CD8 T cells are amongst the earliest islet-infiltrating CD8 T cells in NOD mice. Cloned insulin B15–23-reactive cells (designated G9C8), restricted by H-2K(d), are highly diabetogenic. We used altered peptide ligands (APL) substituted at TCR contact sites, positions (p)6 and 8, to investigate G9C8 T cell function and correlated this with structure. Cytotoxicity and IFN-γ production assays revealed that p6G and p8R could not be replaced by any naturally occurring amino acid without abrogating recognition and functional response by the G9C8 clone. When tested for antagonist activity with APL differing from the native peptide at either of these positions, the peptide variants, G6H and R8L showed the capacity to reduce the agonist response to the native peptide. The antagonist activity in cytotoxicity and IFN-γ production assays can be correlated with conformational changes induced by different structures of the MHC-peptide complexes, shown by molecular modeling. We conclude that p6 and p8 of the insulin B15–23 peptide are very important for TCR stimulation of this clone and no substitutions are tolerated at these positions in the peptide. This is important in considering the therapeutic use of peptides as APL that encompass both CD4 and CD8 epitopes of insulin. WILEY-VCH Verlag 2008-01 /pmc/articles/PMC2901522/ /pubmed/18157812 http://dx.doi.org/10.1002/eji.200737762 Text en Copyright © 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
spellingShingle Molecular immunology
Petrich de Marquesini, Liliana G
Moustakas, Antonis K
Thomas, Ian J
Wen, Li
Papadopoulos, George K
Wong, F Susan
Functional inhibition related to structure of a highly potent insulin-specific CD8 T cell clone using altered peptide ligands
title Functional inhibition related to structure of a highly potent insulin-specific CD8 T cell clone using altered peptide ligands
title_full Functional inhibition related to structure of a highly potent insulin-specific CD8 T cell clone using altered peptide ligands
title_fullStr Functional inhibition related to structure of a highly potent insulin-specific CD8 T cell clone using altered peptide ligands
title_full_unstemmed Functional inhibition related to structure of a highly potent insulin-specific CD8 T cell clone using altered peptide ligands
title_short Functional inhibition related to structure of a highly potent insulin-specific CD8 T cell clone using altered peptide ligands
title_sort functional inhibition related to structure of a highly potent insulin-specific cd8 t cell clone using altered peptide ligands
topic Molecular immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901522/
https://www.ncbi.nlm.nih.gov/pubmed/18157812
http://dx.doi.org/10.1002/eji.200737762
work_keys_str_mv AT petrichdemarquesinililianag functionalinhibitionrelatedtostructureofahighlypotentinsulinspecificcd8tcellcloneusingalteredpeptideligands
AT moustakasantonisk functionalinhibitionrelatedtostructureofahighlypotentinsulinspecificcd8tcellcloneusingalteredpeptideligands
AT thomasianj functionalinhibitionrelatedtostructureofahighlypotentinsulinspecificcd8tcellcloneusingalteredpeptideligands
AT wenli functionalinhibitionrelatedtostructureofahighlypotentinsulinspecificcd8tcellcloneusingalteredpeptideligands
AT papadopoulosgeorgek functionalinhibitionrelatedtostructureofahighlypotentinsulinspecificcd8tcellcloneusingalteredpeptideligands
AT wongfsusan functionalinhibitionrelatedtostructureofahighlypotentinsulinspecificcd8tcellcloneusingalteredpeptideligands